These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19319383)

  • 1. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.
    Sadowski DC; Bernstein CN; Bitton A; Croitoru K; Fedorak RN; Griffiths A;
    Can J Gastroenterol; 2009 Mar; 23(3):185-202. PubMed ID: 19319383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
    Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
    Akobeng AK; Zachos M
    Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease.
    Panteris V; Perdiou A; Tsirimpis V; Karamanolis DG
    World J Gastroenterol; 2006 Oct; 12(38):6235-8. PubMed ID: 17036404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
    Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of adalimumab in the management of refractory Crohn's disease.
    Ho GT; Smith L; Aitken S; Lee HM; Ting T; Fennell J; Lees CW; Palmer KR; Penman ID; Shand AG; Arnott ID; Satsangi J
    Aliment Pharmacol Ther; 2008 Feb; 27(4):308-15. PubMed ID: 18081730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
    Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.